AKT1 and ovarian carcinoma: Only one study implied that overexpression of GLT8D2 confers CDDP resistance to ovarian cancer via activating the FGFR/PI3K/AKT signaling pathway, and suggested that GLT8D2 is a potential therapeutic target for ovarian cancer to enhance platinum response in patients with chemoresistance [18].